Skip to main content
Premium Trial:

Request an Annual Quote

Orchid to Remain Listed on Nasdaq Until at Least June 24

NEW YORK, March 28 - Nasdaq will continue to list Orchid Biosciences' common stock through June 24, the company said today.


Orchid received a delisting warning notice from Nasdaq on Jan. 3 after trading below $1.00, the minimum bid price required for continued listing on the exchange, for several months.The company appealed and a hearing before a Nasdaq listing qualifications panel was held in February.


Last week, Orchid said that Nasdaq had given it permission to go ahead with a private financing of $16 million without seeking shareholders' approval, which the company is hoping to close within the next few days.


Orchid is also seeking shareholder approval for a reverse stock split at a special shareholder meeting scheduled for April 15.


For further information, see the company statement.


The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.